1. In Vivo
  2. >>Business Strategy

Smith & Nephew and Plus Orthopedics: A Deal Drawn to Scale

Smith & Nephew announced that it will buy privately-held Swiss company Plus Orthopedics. The acquisition gives Smith & Nephew a 12% global market share in the total reconstruction market, bumping it up to the global number-four position. S&N officials say the deal is about scale; the combination offers manufacturing leverage, including improved capacity utilization and improvements in the costs of goods. The merged companies also expect to leverage combined sales and marketing capabilities and look for an increase in sales resulting from putting S&N products through Plus sales channels-and vice versa. Some analysts have insisted that the Plus deal is about scale--but they're referring to the bulk that's required for Smith & Nephew to remain independent. S&N has been rumored to be a takeover candidate itself, in an industry in which the number of major players has been steadily shrinking due to consolidation.

A flurry of deal activity—which has seen four acquisitions in as many months—is once again raising the question that industry insiders have asked themselves periodically over the past decade: is the orthopedics industry poised for a wave of significant consolidation? (See Exhibit 1.)Smith & Nephew PLC, which was outbid by Zimmer Holdings Inc. in its attempt to acquire European orthopedics firm Centerpulse AG in 2003--and again recently when a consortium of private equity buyers topped its bid for Biomet Inc.--has become the latest acquirer. [See Deal][See Deal] It announced in March that it would buy privately held Swiss company Plus Orthopedics AG . [See Deal] The acquisition gives Smith & Nephew a 12% global market share in the total reconstruction market, bumping it up to the global number-four position after Zimmer, which has a wide lead with 29% of the market, followed by Johnson & Johnson’s DePuy Inc., which holds a 22% share and Stryker Corp., with 20% of the market. With the Plus acquisition, Smith & Nephew moves just ahead of Biomet.

Smith & Nephew will pay $889 million for Plus, including the assumption of debt. The purchase price is approximately three...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.